• Explore /
  • Poster
  • / MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).

MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).

Abstract Poster

Authors

David Spigel

David R. Spigel

Department of Thoracic Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

David R. Spigel , Maen A. Hussein , Richard Zuniga , Daruka Mahadevan , Robert Winn , Walter C. Darbonne , Bongin Yoo , Young Kim , Zach Whitehead , Ari M. Vanderwalde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Tissue-Based Biomarkers

Clinical Trial Registration Number

NCT04632992

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2612)

DOI

10.1200/JCO.2023.41.16_suppl.2612

Abstract #

2612

Poster Bd #

454

Abstract Disclosures

Similar Posters

First Author: Yuangyuan Zhao

First Author: Shubham Pant

First Author: Yuanyuan Zhao

First Author: Ke-Feng Ding